Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] stock went on a downward path that fall over -5.32% on Thursday, amounting to a one-week price decrease of less than -12.55%.
Over the last 12 months, BCRX stock rose by 33.54%. The one-year Biocryst Pharmaceuticals Inc stock forecast points to a potential upside of 56.48. The average equity rating for BCRX stock is currently 1.18, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.34 billion, with 208.54 million shares outstanding and 197.24 million shares in the current float. Compared to the average trading volume of 3.36M shares, BCRX stock reached a trading volume of 4096345 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Biocryst Pharmaceuticals Inc [BCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $14.73 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 1.18. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wedbush have made an estimate for Biocryst Pharmaceuticals Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on February 25, 2025. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on November 20, 2023, representing the official price target for Biocryst Pharmaceuticals Inc stock. Previously, the target price had yet another raise from $9 to $10, while RBC Capital Mkts kept a Outperform rating on BCRX stock.
The Average True Range (ATR) for Biocryst Pharmaceuticals Inc is set at 0.44, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 2.97.
BCRX Stock Performance Analysis:
Biocryst Pharmaceuticals Inc [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.55. With this latest performance, BCRX shares dropped by -16.86% in over the last four-week period, additionally sinking by -10.97% over the last 6 months – not to mention a rise of 33.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 30.30, with the RSI for the last a single of trading hit 26.96, and the three-weeks RSI is set at 33.90 for Biocryst Pharmaceuticals Inc [BCRX]. The present Moving Average for the last 50 days of trading for this stock 8.01, while it was recorded at 6.65 for the last single week of trading, and 7.68 for the last 200 days.
Insight into Biocryst Pharmaceuticals Inc Fundamentals:
Biocryst Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.58 and a Current Ratio set at 2.63.
Biocryst Pharmaceuticals Inc [BCRX] Institutonal Ownership Details
There are presently around $81.18%, or 82.34%% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 19.96 million shares, which is approximately 9.6676%. VANGUARD GROUP INC, holding 18.77 million shares of the stock with an approximate value of $$116.0 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $$77.68 million in BCRX stock with ownership which is approximately 6.0894%.
